GlaxoSmith Kline, a major manufacturer of anti-diabetes drugs, has decided to sell its Lucozade and Ribena brands — a move that coincides with the release of a major study that shows drinking one can of fizzy drinks a day increases the likelihood of contracting diabetes by 20%.